Background: Gemcitabine (2 0 ,2 0 -difluoro-2 0 -deoxycytidine) is a nucleoside analog used as a single agent and in combination regimens for the treatment of a variety of solid tumors. Several studies have shown a relationship between gemcitabine peak plasma concentration (C max ) and hematological toxicity. An immunoassay for gemcitabine in plasma was developed and validated to facilitate therapeutic drug monitoring (TDM) by providing an economical, robust method for automated chemistry analyzers.
Background: Gemcitabine (2 0 ,2 0 -difluoro-2 0 -deoxycytidine) is a nucleoside analog used as a single agent and in combination regimens for the treatment of a variety of solid tumors. Several studies have shown a relationship between gemcitabine peak plasma concentration (C max ) and hematological toxicity. An immunoassay for gemcitabine in plasma was developed and validated to facilitate therapeutic drug monitoring (TDM) by providing an economical, robust method for automated chemistry analyzers.
Methods: A monoclonal antibody was coated on nanoparticles to develop a homogenous agglutination inhibition assay. To prevent ex vivo degradation of gemcitabine in blood, tetrahydrouridine was used as a sample stabilizer. Validation was conducted for precision, recovery, cross-reactivity, and linearity on a Beckman Coulter AU480. Verification was performed on an AU5800 in a hospital laboratory. A method comparison was performed with (LC-MS/MS) liquid chromatography tandem mass spectrometry using clinical samples. Selectivity was demonstrated by testing cross-reactivity of the major metabolite, 2 0 ,2 0 -difluorodeoxyuridine.
Results: Coefficients of variation for repeatability and withinlaboratory precision were ,8%. The deviation between measured and assigned values was ,3%. Linear range was from 0.40 to 33.02 m/mL (1.5-125.5 mM). Correlation with validated LC-MS/ MS methods was R 2 = 0.977. The assay was specific for gemcitabine: there was no cross-reactivity to 2 0 ,2 0 -difluorodeoxyuridine, chemotherapeutics, concomitant, or common medications tested. Tetrahydrouridine was packaged in single-use syringes. Gemcitabine stability in whole blood was extended to 8 hours (at room temperature) and in plasma to 8 days (2-88C).
INTRODUCTION
Like other cytotoxic agents used in chemotherapy, gemcitabine is dosed by body surface area: a method of dosing that is known not to reduce interindividual variability in clearance and exposure. 1, 2 High interpatient variability is a crucial challenge in chemotherapy, one with grave consequences. Underdosed patients are not deriving the most benefit from the treatment, and there may be tumor progression; overdosed patients may experience toxicity causing delays and changes in regimens. The work to develop and validate an automated Therapeutic Drug Management (TDM) immunoassay was undertaken to provide a clinically accessible tool for dose monitoring of this drug.
Gemcitabine (2 0 ,2 0 -difluoro-deoxycytidine) is a nucleoside analog. 3 It is used as a single agent and in combination regimens to treat non-small cell lung cancer, and pancreatic, breast, bladder, and ovarian cancers. [4] [5] [6] [7] The drug is typically administered as a 30-minute infusion.
Gemcitabine is anabolized in cells by deoxycytidine kinase to monophosphate, diphosphate (dFdCDP), and triphosphate (dFdCTP) nucleotides. The major metabolite 2 0 ,2 0 -difluorodeoxyuridine (dFdU) is produced by the action of the enzyme cytidine deaminase (CDA) (Fig. 1) . 8 At prolonged exposure to clinically achievable concentrations, dFdU has cytotoxic effects by itself, but its contribution to gemcitabine's activity is not clear yet. 9 Grade 3-4 hematological toxicities of gemcitabine occur frequently. [10] [11] [12] Several studies have shown a relationship between gemcitabine peak plasma concentration (C max ) and hematological toxicity. 13, 14 Kroep et al found a correlation between the decrease in platelets and the gemcitabine C max , with a .50% decrease at C max concentration .20 mM (5.26 m/mL). 13 A 2001 study of patients with non-small cell lung cancer by Fogli et al 14 found a correlation between gemcitabine C max and reduction in platelet counts.
The concentrations to be targeted may depend on the schedule and combinations but are likely to be in the range of 20 mM (around 5 m/mL), and therefore this range may be the concentration of clinical interest to target in TDM. [15] [16] [17] [18] Patients with plasma concentrations above ;14 m/mL showed significant hematological toxicities. 14, 19 
MATERIALS AND METHODS

Sample Stabilizer
Gemcitabine is rapidly metabolized in blood by CDA. Tetrahydrouridine (THU) is a known inhibitor of CDA (Fig.  1) . THU has been used by a number of investigators in clinical studies to stabilize gemcitabine in whole blood and plasma. 13, 18, [20] [21] [22] To facilitate handling in a clinical setting, a stabilizer kit was developed consisting of a single-use syringe containing 100 mL of 500 mg/mL THU. The stabilizer was injected into the blood collection tube using a BD Vacutainer Blood Transfer Device (Becton Dickinson, Franklin Lakes, NJ). With the entire contents of the syringe injected into a 4-mL blood collection tube, the final concentration of THU was 125 m/mL. All plasma used in the validation of the assay contained the sample stabilizer as would a patient sample.
To verify the effectiveness of the sample stabilizer to stop degradation of gemcitabine by CDA, stability studies were performed to mimic different handling scenarios for whole blood and its processing into plasma. Human blood was drawn into 4-mL blood tubes, spiked with gemcitabine, and then the sample stabilizer was added within 6 minutes. Portions of the blood were processed at time zero to demonstrate that adding stabilizer within 6 minutes was acceptable, and periodically thereafter to determine the stability of gemcitabine in whole blood at room temperature and in plasma processed from that whole blood and stored at 2-88C. The following anticoagulants were tested: K 2 EDTA, K 3 EDTA, sodium citrate, sodium heparin, lithium heparin, lithium heparin with gel (Plasma Separator Tube, or "PST"), and sodium fluoride.
Assay Method
The principle of the current assay has been described previously and represents a standard approach for a homogeneous nanoparticle immunoassay. 23, 24 The assay comprises 2 liquid reagents. Reagent 1 contains a large polymer with repeating units of a gemcitabine derivative. Reagent 2 comprises 200-nm polystyrene nanoparticles to which antibodies are covalently attached. When the 2 reagents are mixed, the antibody particles react with the gemcitabine polymer to form an agglutination complex that can be monitored spectrophotometrically. The larger the complex, the more the light is scattered, resulting in an increase in the net absorbance by the solution. The amount of light scattering is proportional to r 6 , where r is the radius of the complex. When free gemcitabine is present in the sample, it competes with the drug conjugate for the limited antibody. The higher the concentration of gemcitabine, the smaller the agglutination complexes formed and the less light that is scattered. This results in a decreasing calibration curve: maximum absorbance in the absence of analyte in the sample and decreasing absorbance proportional to the amount of analyte present. The assay was designed to measure the concentration of gemcitabine observed in patient plasma at C max of a 30-minute infusion. The reagent formulations were optimized to maintain performance over a shelf-life of 24 months.
The major metabolite of gemcitabine is dFdU and is present at concentrations greater than the parent drug at the end of infusion. The gemcitabine monoclonal antibody used in the assay is selective for the parent drug and has low crossreactivity to the related compounds dFdU and THU. The immunogen for the monoclonal antibody program was prepared by derivatizing gemcitabine from the 5 0 -hydroxyl moiety and covalently attaching the compound to the immunogenic protein carrier keyhole limpet hemocyanin. The derivative preparation, immunogen, and antibody generation has been described previously. 25 The gemcitabine reagent kit is manufactured by Saladax Biomedical (Bethlehem, PA). The reagent kit consists of 2 Beckmann Coulter AU (Brea, CA) compatible bottles: one bottle contains the reaction buffer with a polymeric gemcitabine conjugate (R1), and the other bottle contains the monoclonal antibody-coated nanoparticle (R2). The kit contains enough reagents to perform 100 tests on the analyzer. The AU480 is an open clinical analyzer, and the assay parameters are applicable to other Beckman Coulter instruments in the AU family. The analyzer pipettes 95 mL of R1 and 2 mL of sample into a reaction cuvette. After an incubation time of 3.4 minutes, 95 mL of R2 is added. Mixing occurs after each step. The agglutination reaction is monitored at 600 nm. The calculated reaction endpoint is inversely proportional to the concentration of gemcitabine present in the sample.
Validation studies were run on an AU480 clinical analyzer. The performance of the assay was verified in a second laboratory on an alternative (AU5800) analyzer.
Calibrators, Controls, Calibration Curve, and Calibration Interval
The gemcitabine concentrations of the calibrators were 0.00, 1.00, 3.00, 8.00, 15.00, and 30.00 m/mL (0.00, 3.80, 11.4, 30.4, 56.99, and 114.0 mM). The low, medium, and high assay control concentrations, 2.00, 10.00, and 25.00 mcg/mL, respectively (7.60, 37.99, and 94.99 mM), were selected to ensure accurate quantification at medical decision points. Calibrators and controls were formulated in a buffer matrix for ease of use and stability. The calibration interval (standard curve stability) was the length of time that a kit generated quality control (QC) results within specifications without a recalibration. The kits were stored at 2-88C during the study. The calibration interval was established using 3 lots of reagents. Calibrations were performed on day 0; thereafter, assay controls of each concentration were run in singlicate at defined intervals (every 3-4 days). The calibration interval was maintained when control results met the recovery specifications of 615% for the low or 610% for the medium and high controls.
Precision
Precision was determined according to CLSI Guideline EP05-A3. 26 To evaluate repeatability and withinlaboratory precision, drug-free plasma pools spiked at 1.50, 4.00, 12.50, and 27.50-mcg/mL (5.70, 15.20 47.49, 104.5 mM) gemcitabine, and the 3 assay controls were tested in duplicate in 2 runs per day (separated by at least 2 hours) to generate 20 days of data without outliers. To identify outliers during daily testing, the difference between each pair of replicates within a run was compared with an outlier threshold determined early in the study by testing the precision study samples (n = 20) in a single run. The threshold for each precision study sample was equal to 5.5 times the SD of the results from the n = 20 run, and differences between replicates that exceeded this threshold caused the run to be repeated on a different day. The repeatability and within-laboratory SD and coefficient of variation (CV) were calculated with EP Evaluator Release 9, EP5 Precision module (version 9.0.0.366; Data Innovations). Precision performance was verified on an AU5800 in an external hospital laboratory using an abbreviated protocol similar to CLSI guideline EP15-A3. 27 For the performance verification, controls were measured in duplicate twice a day, with runs separated by at least 2 hours, for 5 days.
Limit of Detection (LOD) and Limit of Quantification
The LOD and limit of quantification (LOQ) were tested according to CLSI Guideline EP17-A2. 28 Individual normal human (drug-free) K 2 EDTA plasmas spiked with gemcitabine were used to determine the LOD (5 plasma samples) and LOQ (4 plasma samples). The samples were spiked around the estimated limits. Samples were analyzed n = 3 using 3 reagent lots on 2 analyzers. LOD was tested over 2 days and LOQ over 3. Limit of blank (LOB) was determined in the same experiment by testing the 5 drug-free human plasmas n = 3 over 2 days. The LOB was the 95th percentile result for drug-free plasma. The LOD was the gemcitabine concentration at which 95% of the results were greater than the assay LOB. The LOQ was the gemcitabine concentration at which the total analytical error (TAE) calculated by the Westgard model (TAE = bias + 2 · SD) was #35%. 29 For the external LOQ verification, the hospital laboratory ran the 4 samples containing gemcitabine at the assay LOQ over 2 days on an AU5800. Fifty-four of the 60 results were required to be between 0.55 and 1.15 mcg/mL: LOQ 6 35% (TAE).
Linearity
Assay linearity testing was conducted according to CLSI Guideline EP6-A. 30 Drug-free pooled normal human K 2 EDTA plasma was selected as the sample matrix because patient samples from individuals being treated with gemcitabine were not available in sufficient quantity. Gemcitabine was spiked into the plasma at 0.40 (1.52 mM) and 33.02 m/mL (125.46 mM). These were combined in 11 different proportions to generate a 13-level linearity testing set. Three of the 13 levels were below the assay limit of quantification: 2 of those samples, 0.04 and 0.06 m/mL (0.15 and 0.23 mM), were eliminated from the analysis because of the large total error associated with measuring concentrations far below the LoQ; the third sample (0.80 m/mL) was included in the analysis to demonstrate that the linear range of the assay included the LOQ. The linear range of the assay was determined from the lowest and highest linearity samples between which all linearity samples (tested n = 5) met the mean deviation (0.8 # X , 1 m/mL: 620%; 1 # X , 1.5 m/mL: 16%; 1.5 # X , 5.39: 611%; 5.39 # X # 33.02 m/mL: 68%) and deviation from linearity (#15%) acceptance criteria across 3 lots of reagents on 2 analyzers. In addition, the range of samples meeting those criteria had to contain at least 9 levels. For the external assay linearity verification, the hospital laboratory tested the same samples described above on an AU5800.
Recovery of Gemcitabine
To validate the ability of the assay to determine gemcitabine concentrations without patient-to-patient bias, gemcitabine was spiked into 5 individual drug-free normal plasmas at 4 concentrations (1.50, 4.00, 12.50, and 27.50 m/mL) covering the range of the assay. All samples were analyzed n = 5 on 2 analyzers with 3 lots of reagents. Replicate recoveries were calculated from spiked gemcitabine results and compared with assigned values. For the external recovery verification, the hospital laboratory tested 2 plasma pools (n = 20 on 2 days) and 5 patient samples (n = 2) containing known levels of gemcitabine on an AU5800.
Cross-Reactivity
The major gemcitabine metabolite dFdU, the sample stabilizer THU, common prescription and over-the-counter medicines, vitamins, herbal supplements, and structurally related compounds (including cytidine derivative antivirals) were tested for cross-reactivity (see Table S1 , Supplemental Digital Content 1, http://links.lww.com/TDM/A185 for a complete listing). Testing was conducted according to the CLSI guideline EP07-A2. 31 Cross-reactivity was assessed in a drug-free plasma pool, and the same pool spiked with 4 m/mL of gemcitabine. The samples were evaluated with one lot of reagent on 2 analyzers. Compounds were dissolved in a suitable solvent and spiked into plasma pools at a minimum concentration of 100 m/mL. The cross-reactivity was calculated from the difference of the mean gemcitabine values with and without cross-reactant divided by the cross-reactant concentration.
Interference
Interference from lipemia, icterus, total protein, hemolysis, and rheumatoid factor was evaluated. Bilirubin, human serum albumin (HSA), and immunoglobulin G (IgG) were spiked into a drug-free plasma pool, and this plasma pool was spiked with gemcitabine to a concentration of 4 m/mL. To prepare lipemic samples, the lipid layer isolated from fresh human plasma was spiked into the plasma pools for interference testing. The concentrations of bilirubin, HSA, IgG, and lipemia were verified using reagent kits from JAS Diagnostics. Rheumatoid factor (Keystone Biologicals) was spiked into plasmas from a known stock concentration. Hemolysate was prepared from blood obtained from healthy donors, and known hemoglobin concentrations were spiked into plasma samples to simulate hemolyzed samples.
Comparative Methods
Two comparative methods were used for the method comparison. The second one was used when additional samples were obtained.
In the first method, gemcitabine was quantitated using an Agilent 1100 autosampler and binary pump (Agilent Technologies, Palo Alto, CA) coupled to a Micromass Quattro Micro triple-stage bench-top mass spectrometer (Waters, Milford, MA). Analytes were separated on a Shodex Asahipak NH2P-50 2D column (5 mm, 2 · 150 mm). The gradient mobile phase system comprised solvent A (acetonitrile with 0.1% formic acid) and solvent B (water with 0.1% formic acid). The initial mobile phase was 98% A and 2% B at a flow rate of 0.2 mL/min. Subsequently, solvent B was increased to 20% over 10 minutes, where it was held for 2 minutes. Solvent B was increased to 60% in 6 seconds for 1 minute 50 seconds with a flow rate of 0.7 mL/min and then decreased to 0% at 14.1 minutes and held until 18.2 minutes. Finally, B increased to 2% from 18.3 to 19.8 minutes when the flow rate was returned to 0.2 mL/min and was followed by injection of the next sample. Mass spectrometer settings were as follows: capillary voltage 4 kV; cone voltage 20; and desolvation temperature 3508C. The MRM m/z ratios monitored were m/z . 264.1 . 112.1 and 267.1 . 115.1 for dFdC (Fig.  2 ) and 15 N 2 , 13 C-dFdC (internal standard), respectively. Aliquots of 100 mL of plasma were mixed with 10 mL of internal standard (1 m/mL in water) and were then extracted with 10 m L of glacial acetic acid and 1 mL of ethyl acetate. After vortexing and centrifugation, the supernatant was transferred to a 12 · 75 mm borosilicate glass tube, and the solvents were evaporated under nitrogen at 378C. Samples were reconstituted with 100 mL of acetonitrile:water (98:2 v/v), transferred to an autosampler vial, and 5 mL of the sample was injected into the LC-MS/MS system. The ion chromatograms were integrated and quantified using Micromass Masslynx Version 4.0 (Waters). The linearity of this assay was 10-5000 ng/mL. This assay had an acceptable accuracy (#15% 31 ) based on duplicate QCs (30, 500, and 2000 ng/mL gemcitabine and dFdU) and duplicate calibrators (10, 20, 50 , 100, 200, 500, 1000, 2000, and 5000 ng/mL of gemcitabine and dFdU) on 3 separate days resulting in good accuracy (gemcitabine 95.4%-107.1%; dFdU 95.9%-107.6%) and precision (#15% 32 ) (gemcitabine ,5.4% CV; dFdU ,8.0% CV).
The second LC-MS/MS method was developed and validated by inVentiv Health Clinical (Princeton, NJ) and was proprietary.
Clinical Samples and Method Comparison
Heparinized blood samples collected in BD Vacutainer were deidentified according to an exempt institutional review board study approved by the University of Pittsburgh Institutional Review Board. These samples were stored at 2808C and analyzed by LC-MS/MS. In addition, archived samples were provided by the VU University Medical Center. These samples were tested by inVentiv Health Clinical. Each sample was tested n = 1 using each method. Results for both comparator methods were adjusted to account for differences in standardization. Samples with results below the gemcitabine assay LOQ were immediately excluded, and the remaining data were examined for outliers. Samples with disproportionately high influence were identified by calculating standardized residuals and leverages using Minitab 17 (Minitab, State College, PA. 2015). One sample was excluded because its standardized residual of 7.9 was outside the limits of 23 to +3, indicating that it was an outlier. 26 A second sample was excluded because its leverage of 0.435 exceeded the limit of 0.092 [or, 3 · (the number of terms in the model/the number of observations)], indicating that it was exerting a disproportionately large influence on the regression. 33 A total of 63 patient samples were used in the final Deming regression analysis. 34 
RESULTS
Sample Stability
There was no significant (#8%) loss of gemcitabine in whole blood when sample stabilizer was added to the whole blood within 6 minutes; recoveries compared with the theoretical value ranged from 92% to 103% for the following anticoagulants: K 2 EDTA, K 3 EDTA, sodium heparin, lithium heparin, and lithium heparin in a Plasma Separator Tube. More degradation (.10% loss) of gemcitabine was observed in sodium citrate and fluoride tubes, and these were considered unacceptable. After the addition of sample stabilizer, the gemcitabine was stable in whole blood for at least 8 hours when stored at room temperature and 24 hours when stored at 2-88C. Gemcitabine was stable for at least 7 days in plasma prepared from whole blood with stabilizer stored at room temperature for 8 hours or at 2-88C for 24 hours.
Calibration Curve and Calibration Interval
The assay covers the range of expected results using 6 calibrators, 0.00, 1.00, 3.00, 8.00, 15.00, and 30.00 m/mL (0, 3.80, 11.4, 30.4, 56.99, and 114.0 mM), with a 4 parameter logistic regression curve fit. The calibration curve is shown in Figure 3 . The analyzer was programmed to automatically dilute samples higher than 30 m/mL by 1:2 (1 part specimen + 2 parts diH 2 O). This gives the assay an effective range up to 90 m/mL (342.0 mM). When the reagents were calibrated on day 0, control values remained within specification for at least 6 weeks, during which time no recalibration of the instrument was required. Recalibration after controls failed brought control recovery within specifications.
Precision
Repeatability and within-laboratory precision were determined for samples prepared from a drug-free plasma pool spiked with gemcitabine at 4 concentrations, 1.50, 4.00, 12.50, and 27.50 m/mL (5.70, 15.20 47.49, and 104.5 mM) and the assay controls at 3: 2.00, 10.00, and 25.00 m/mL (7.60, 37.99, and 94.99 mM). The CVs for repeatability were between 1.3% and 3.1% (Table 1 ). The within-laboratory CV ranged from 3.3% to 7.5%. The highest CV occurred at the lowest plasma concentration (Table 1 ). In the external laboratory, CVs were between 2.2% and 6.0% for repeatability and between 2.2% and 6.7% for within-laboratory precision.
Linearity
The immunoassay was linear from 0.80 to 33.02 m/mL. The greatest mean deviation from linearity was less than 3% and mean recoveries were between 95% and 118%. For linearity samples in the test range (LoQ to 30 m/mL), the recovery was between 95% and 107%. In the external laboratory, mean recoveries were between 92% and 101%.
Recovery
The recovery of gemcitabine in 5 individual plasmas ranged from 82% to 118% at 1.50 m/mL (5.70 mM), 89%-111% at 4.00 m/mL (15.2 mM), and 90%-110% at 12.50 (47.49 mM) and 27.50 m/mL (104.5 mM). In the external laboratory, the recovery results for 5 plasmas containing gemcitabine at concentrations ranging from 1.26 to 7.54 m/mL (4.79-28.6 mM), measured twice, were 103%-122%.
Limit of Detection and LOQ
The assay LOQ was 0.85 m/mL (3.2 mM), the lowest gemcitabine concentration for which the total analytical error was ,35%. The LOD was 0.44 mcg/mL (1.7 mM): 95% of the results at this concentration exceeded the assay LOB. The LOQ was confirmed in the external laboratory when 58 of 60 results from the analysis of 4 plasmas spiked with gemcitabine at 0.85 m/mL were within 635% of expected.
Cross-Reactivity
Over 110 compounds were tested for cross-reactivity to determine whether they would influence assay results (see Table S1 , Supplemental Digital Content 1, http://links.lww. com/TDM/A185 for a complete listing). No assay interference from the tested compounds was found. The cross-reactivities of the major metabolite (dFdU) and the stabilizer (THU) were ,0.1%. The cross-reactivity of cytosine and cytidine were #0.1%, and the cross-reactivity of deoxycytidine was #0.8%. All compounds tested had ,1% influence on the assay.
Interference
The following endogenous interferents were tested in the assay: lipemia, icterus, total protein, hemolysis, and rheumatoid factor. The effect on the assay ranged from 28% to 3% (Table 2) . No significant interference was observed from the following interferents: rheumatoid factor at 550 IU/mL, HSA at 6 g/dL, human IgG at 6 g/dL, icteric samples at 34 mg/dL, lipemic samples at 521 mg/dL, and hemolysate samples at 1100 mg/dL. The Deming regression of the data set had a slope of 1.006 (95% confidence interval: 0.962-1.050) with a y-intercept of 20.218 (95% confidence interval: 20.628 to 0.193), a standard error of the estimate of 0.937, and a correlation coefficient of 0.9855 (Fig. 4) . Bias to the average of the methods ranged from 216% to +6% with an average bias of 20.09 mcg/mL (0.3 mM). Sixty-one samples measured by the immunoassay deviated ,1 m/mL (,4 mM) from the average of the methods.
Method Comparison
DISCUSSION
Physical methods to quantify analytes of interest are often considered, and with good reason, the gold standard to which immunoassays are compared. To eliminate interference from matrix or related substances, they use pretreatment of samples and chromatography for separation and various detection methods, such as ultraviolet spectrometry or mass spectrometry. Numerous methods have been used for the detection of antimetabolite chemotherapeutics including gemcitabine. 20, [35] [36] [37] [38] [39] Most pharmacokinetic studies not only in oncology and in Phase I studies, but also in TDM are done by chromatographic methods also because they have the advantage of determining several analytes simultaneously. 40 However, in contrast to a commercial liquid reagent that can be run on a clinical chemistry analyzer, physical methods require method development, additional validation, special equipment, and technical expertise. To make testing of chemotherapeutics easily accessible to any laboratory with a clinical chemistry analyzer with user-defined channels and to support a planned clinical trial, we sought to develop an automated immunoassay for gemcitabine. To ensure the correct selectivity of the assay, and absence of matrix effects, a method comparison was performed using LC-MS/MS. For lot-to-lot consistency, a monoclonal antibody was selected for the assay. Although monoclonal and polyclonal antibodies to uracil, 5-fluorouracil, and 5-fluoro-2 0 deoxyuridine-5 0 -monophosphate have been published, this is the first homogeneous immunoassay reported for gemcitabine, which we know of, using a monoclonal antibody. [41] [42] [43] Gemcitabine has a very short half-life of approximately 8 minutes with wide interpatient variability. 18, 39 This makes the use of sample stabilizer necessary. Even with a stabilizer, many clinical studies in the literature report placing samples on ice and/or immediate centrifugation and freezing before measuring. 13, 14, 17, 19, 39, 44 This is not so practical in routine clinical settings. The demonstration of stability in whole blood with a premeasured stabilizer simplifies blood processing. Adding stabilizer to the blood within minutes after the draw extended the window within which plasma must be isolated, eliminating the need for any ice. This is a critical advantage to sample handling for routine TDM testing. We demonstrated that gemcitabine was stable for 8 hours at ambient room temperature and 48 hours at 2-88C before being processed into plasma.
The assay was optimized to measure C max of a 30-minute infusion. As a routine TDM tool, this is the most practical pharmacokinetic parameter: only 1 blood sample is required at the end of infusion, and there is no requirement for the patients to stay for a second sample to be drawn. Although some studies have suggested the clinical utility of monitoring C max , a clinical trial is planned to validate the association of C max with toxicity and outcomes. 13, 14 The limit of quantification for the assay was 0.85 m/mL. This is, as would be expected for an immunoassay, higher than those published for physical methods that incorporate a separation step to remove matrix interference and use sensitive detection techniques such as tandem mass spectrometry. 16, 35, 37, 45 Measurement of the C max would not be affected, as values .210 mM (2.63 m/mL) have been reported for the clinically common doses around 1000 mg/m 2 . 13, 18, 19, 39 A turbidimetric immunoassay was developed with a monoclonal antibody selective for gemcitabine that is not affected by the metabolite dFdU and the blood stabilizer THU. The assay was formulated with 2 reagents so that it can be performed on most clinical chemistry analyzers with utility or open channels.
Performance was demonstrated with gemcitabinespiked plasma containing stabilizer at concentrations below, within, and above the suggested range of 10-20 mM. [46] [47] [48] Having demonstrated acceptable analytical performance according to CLSI protocols and the appropriate selectivity in comparison to LC-MS/MS, the assay is suitable as a tool for TDM. Given the association of gemcitabine C max with toxicity, and the wide interpatient variability that has been demonstrated, the management of gemcitabine therapy may be improved with TDM. 13, 14 
CONCLUSION
The assay evaluated in this report is the first automated immunoassay for the management of gemcitabine therapy. A reliable analytical performance validated by CLSI methods was demonstrated. This assay can be used in clinical studies to confirm the utility of therapeutic blood monitoring in patients being treated with gemcitabine.
